First Patient Enrolled In Global Phase III Study Of Bevacizumab And Trastuzumab In Early Breast Cancer

PARIS -- Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted therapy trastuzumab (Herceptin(R)), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer. "Trastuzumab is already the standard of care across all stages of HER2-positive breast can...